metformin has been researched along with Affective Disorders in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale." | 5.91 | Metformin is Protective Against the Development of Mood Disorders. ( Berk, M; Bortolasci, CC; Crowley, T; Dean, OM; Kidnapillai, S; Kim, JH; Lake, J; Liu, ZSJ; Panizzutti, B; Pasco, JA; Richardson, M; Spolding, B; Stuart, AL; Truong, TTT; Walder, K; Williams, LJ, 2023) |
| "To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish possible effects of oral anti-hyperglycemic agents (OAAs)." | 5.38 | Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. ( Chang, HY; Chuang, SY; Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML; Yu, SH, 2012) |
| "Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale." | 1.91 | Metformin is Protective Against the Development of Mood Disorders. ( Berk, M; Bortolasci, CC; Crowley, T; Dean, OM; Kidnapillai, S; Kim, JH; Lake, J; Liu, ZSJ; Panizzutti, B; Pasco, JA; Richardson, M; Spolding, B; Stuart, AL; Truong, TTT; Walder, K; Williams, LJ, 2023) |
| "To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish possible effects of oral anti-hyperglycemic agents (OAAs)." | 1.38 | Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. ( Chang, HY; Chuang, SY; Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML; Yu, SH, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lake, J | 1 |
| Bortolasci, CC | 1 |
| Stuart, AL | 1 |
| Pasco, JA | 1 |
| Kidnapillai, S | 1 |
| Spolding, B | 1 |
| Truong, TTT | 1 |
| Panizzutti, B | 1 |
| Liu, ZSJ | 1 |
| Dean, OM | 1 |
| Crowley, T | 1 |
| Richardson, M | 1 |
| Kim, JH | 1 |
| Berk, M | 1 |
| Williams, LJ | 1 |
| Walder, K | 1 |
| Linneke, JL | 1 |
| Jørgensen, GK | 1 |
| Csillag, C | 1 |
| Ying, MA | 1 |
| Maruschak, N | 1 |
| Mansur, R | 1 |
| Carvalho, AF | 1 |
| Cha, DS | 1 |
| McIntyre, RS | 1 |
| Wahlqvist, ML | 1 |
| Lee, MS | 1 |
| Chuang, SY | 1 |
| Hsu, CC | 1 |
| Tsai, HN | 1 |
| Yu, SH | 1 |
| Chang, HY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Metformin Treatment on Cognitive Impairment in Patients With Schizophrenia Co-morbid Metabolic Syndrome: a Prospective Cohort Study[NCT03271866] | 80 participants (Anticipated) | Interventional | 2017-08-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Affective Disorders
| Article | Year |
|---|---|
Metformin: repurposing opportunities for cognitive and mood dysfunction.
Topics: Cognition Disorders; Humans; Metformin; Mood Disorders; Nootropic Agents | 2014 |
3 other studies available for metformin and Affective Disorders
| Article | Year |
|---|---|
Metformin is Protective Against the Development of Mood Disorders.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Mood Disorders; Retrospective Studies | 2023 |
Metformin for weight loss and control in patients with mood disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypoglycemic | 2014 |
Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellit | 2012 |